Abbott’s Metabolic Biowearable Gets ‘Extremely Positive’ UK Reception; Next Up, US Filing

“We’re so steeped in scientific and medical expertise that we never really learned how to talk to or with regular people,” says Abbott CEO Robert Ford.

Medtech Insight caught up with Abbott’s division VP of Lingo Biowearables at HLTH to learn more about its recent UK launch and future plans.

HLTH conference 2023
• Source: Medtech Insight

It’s been two months since Abbott’s new biosensing wearable Lingo, designed to enable consumers to monitor their metabolic health, made its debut in the United Kingdom. And thus far, the reception in that test market has been “extremely positive,” Olivier Ropars, division vice president of Abbott’s Lingo Biowearables told Medtech Insight at the HLTH conference last week.

Abbott plans to file for US Food and Drug Administration clearance of the device by year-end and then make Lingo...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Digital Technologies

Surgical Robotics CEOs Talk Metrics For Success, Valuations, Competition And IPO Outlook

 
• By 

Leaders of robotic systems companies Distalmotion, Neocis and Noah Medical discussed success metrics, competition and funding. Institutional investors are focusing on utilization, procedure rates and a clear path to profitability as the IPO window reopens, BTIG analyst Ryan Zimmerman said.

Dxcover Launches US Operations With New Headquarters In Tennessee

 

Dxcover sets up new Clinical Laboratory Improvement Amendments (CLIA) lab in Franklin, Tennessee.

Fallouh Healthcare Receives Grant Funding From Innovate UK

 

Fallouh Healthcare has received £305,050 in grant funding from Innovate UK as part of the European Union’s Eureka Eurostars program. The company aims to detect cardiac tamponade, a condition that affects patients after heart surgery. Currently, there is no way to accurately diagnose the condition.

Will Kennedy And Makary Come To Terms On User Fees During Next Round Of MDUFA Negotiations?

 

It’s no secret that Marty Makary and Robert F. Kennedy Jr. have a different take on user fees, with Makary viewing them as a funding necessity and Kennedy as a corrupting influence. But will they find a way to strike a balance during the next MDUFA reauthorization talks so each can claim victory?

More from Medtech Insight

Execs On The Move: June 16–20, 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Dxcover Launches US Operations With New Headquarters In Tennessee

 

Dxcover sets up new Clinical Laboratory Improvement Amendments (CLIA) lab in Franklin, Tennessee.

EnsoData Boosts AI Sleep Tech With $20M Series B Funding, Targets Underdiagnosis Crisis

 
• By 

EnsoData positions itself as device-agnostic and interoperable, with FDA-cleared software that can integrate with all major devices. CEO Mortara said this flexibility helps maximize patient reach by enabling both direct provider engagement and integration with device manufacturers.